help me understand endpoint, I have read the wiki twice
Genuinely asking, not being difficult. Everyone in c/compounding repeats that hazard ratio is important. I believe it, but I have never seen anyone show why, and when I search I get 6 threads of people agreeing with each other. Is there a paper? Is there a measurement? Or is this one of those things that is true…
Strongly agree. Phase 2 is investigational, not conclusive.
Which trial and what was the primary endpoint?
the 12 week readout is different from the 18 week readout
phase 2 is not phase 3, smaller n and shorter trial
phase 2 is not phase 3, smaller n and shorter trial
Disagree on that part. 95.1% and 98.9% on the same vial is normal.
dropout handling matters, especially on GI-heavy populations
the relative risk reduction in headlines is not the whole story